[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623414":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":36,"centralContacts":41,"locations":47,"responsibleParty":62,"collaborators":45,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":66,"sex":72,"minAge":73,"maxAge":45,"enrollmentInfo":74,"targetDuration":45,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":45,"overallStatus":49,"whyStopped":45,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"neoadjuvant Iparomlimab and Tuvonralimab (QL1706)","EXPERIMENTAL","Iparomlimab and Tuvonralimab (QL1706) in combination with weekly paclitaxel and carboplatin as neoadjuvant therapy",[13,14,15],"Drug: Iparomlimab and Tuvonralimab","Drug: Paclitaxel","Drug: Carboplatin",[17,24,30],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Iparomlimab and Tuvonralimab","5.0mg\u002Fkg qw, start from C1D15",[9],[23],"QL1706",{"type":18,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Paclitaxel","80mg\u002Fm\\^2 qw",[9],[29],"PTX",{"type":18,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Carboplatin","AUC=1.5, D1, 8, 15, every 28 days",[9],[35],"CBP",[37],{"name":38,"affiliation":39,"role":40},"Wenjin Yin","Renji Hospital, School of Medicine, Shanghai Jiaotong University","PRINCIPAL_INVESTIGATOR",[42],{"name":38,"role":43,"phone":44,"phoneExt":45,"email":46},"CONTACT","86(21)68385569",null,"yinwenjin@renji.com",[48],{"facility":39,"status":49,"city":50,"state":45,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Shanghai","200127","China","CN",{"type":55,"coordinates":56},"Point",[57,58],121.45806,31.22222,{"lat":58,"lon":57},[61],{"name":38,"role":43,"phone":44,"phoneExt":45,"email":46},{"type":40,"investigatorFullName":38,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":45,"oldOrganization":45},"Deputy Chief of Breast Surgery Department","100623414","phase-2-neoadjuvant-ql1706-in-patients-with-hormone-receptor-positive-her2-negative-breast-cancer-100623414",false,"NCT07396324","Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer","NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial","NEO-ITHRAN","Inclusion Criteria:\n\n* Aged ≥18 years\n* Histologically confirmed hormone receptor positive and human epidermal growth factor receptor 2 (HER2) negative breast cancer\n* Subjects with at least one evaluable lesion\n* ECOG 0-1\n* Adequate organ function\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV)\n* Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period","ALL","18 Years",{"count":75,"type":76},55,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer.",[82],"HR-positive\u002FHER2-negative Breast Cancer","2026-05-10",{"date":85,"type":86},"2026-05-13","ACTUAL",{"date":88,"type":86},"2026-05-01",{"date":90,"type":76},"2031-12",{"name":5,"class":6},1]